CRISPR Therapeutics(US:CRSP) ZACKSยท2024-10-21 23:06Company Performance - CRISPR Therapeutics AG closed at $48.51, reflecting a -0.84% change from the previous day, which is worse than the S&P 500's daily loss of 0.18% [1] - The stock has increased by 1.54% over the past month, while the Medical sector has declined by 3.03% and the S&P 500 has gained 4.46% [1] - The upcoming earnings disclosure is anticipated, with expected EPS of -$1.33, representing a 5.67% increase from the prior-year quarter [1] - For the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.55 per share and revenue of $64.2 million, indicating changes of -186.08% and -82.7% from the previous year [1] Analyst Estimates - Recent changes to analyst estimates for CRISPR Therapeutics AG reflect evolving short-term business trends, with upward revisions indicating analysts' positivity towards the company's operations [2] - The Zacks Rank system, which includes estimate changes, has shown that 1 ranked stocks yield an average annual return of +25% since 1988 [2] - Over the past month, there has been a 0.52% rise in the Zacks Consensus EPS estimate, and CRISPR Therapeutics AG currently holds a Zacks Rank of 2 (Buy) [2] Industry Overview - The Medical - Biomedical and Genetics industry is part of the Medical sector and currently holds a Zacks Industry Rank of 87, placing it in the top 35% of over 250 industries [3] - The Zacks Industry Rank measures the strength of industry groups by the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [3]